The primary objective of the multicenter, randomized, placebo-controlled, crossover study is assessment of safety, tolerability and efficacy of ARX-02 relative to placebo in cancer patients experiencing episodic breakthrough pain. ‘We are very happy to have initiated the dosing of our initial patient in this proof-of-concept research,’ states AcelRx Chief Executive Officer Thomas Schreck. ‘Developing a fastacting opioid with a shorter half-life than fentanyl for cancer patients who experience unexpected breakthrough discomfort represents a significant step towards effectively treating discomfort while minimizing general opioid exposure.’ Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for many pancreatic cancers patientsCornell biomedical engineers develop 'super natural killer cells' to destroy cancer cells in lymph nodesNew findings reveal association between colorectal melanoma and cancer medication treatmentPamela Palmer, MD, PHD, AcelRx Chief Medical Officer adds, ‘The pharmacokinetic profile of ARX-02 can be optimal because of this patient population.Increased intestinal permeability offers been reported in patients with IBS. However, there are no reviews of characteristic endoscopic findings which define IBS. Experts at University of Alberta in Canada hypothesized that increased epithelial cell extrusion might bring about intestinal barrier dysfunction. Intestinal epithelial cells are shed, leaving gaps in the epithelial coating. In this prospective controlled cohort research of 17 IBS sufferers and 18 healthy handles, Dr.